Compare · MDLN vs VVOS
MDLN vs VVOS
Side-by-side comparison of Medline Inc. (MDLN) and Vivos Therapeutics Inc. (VVOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and VVOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 3673.2x VVOS ($12.1M).
- Over the past year, MDLN is down 17.1% and VVOS is down 59.1% - MDLN leads by 42.0 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 5 for VVOS).
- MDLN has more recent analyst coverage (25 ratings vs 1 for VVOS).
- Company
- Medline Inc.
- Vivos Therapeutics Inc.
- Price
- $33.80+0.58%
- $0.87+0.12%
- Market cap
- $44.40B
- $12.1M
- 1M return
- -19.55%
- +31.55%
- 1Y return
- -17.07%
- -59.11%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2020
- News (4w)
- 20
- 5
- Recent ratings
- 25
- 1
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest VVOS
- Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure
- Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
- SEC Form 10-Q filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
- SEC Form NT 10-Q filed by Vivos Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Vivos Therapeutics Inc.
- SEC Form EFFECT filed by Vivos Therapeutics Inc.
- SEC Form 424B3 filed by Vivos Therapeutics Inc.
- Amendment: SEC Form S-3/A filed by Vivos Therapeutics Inc.